Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Long Term Follow-Up of Sulfur Mustard Related Bronchiolitis Obliterans Treatment Pubmed



Abtahi H1, 2 ; Peiman S1, 3 ; Foroumandi M3 ; Safavi E1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pulmonary and Critical Care, Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pulmonary and Critical Care, Imam Khomeini Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Internal Medicine, Imam Khomeini Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Acta Medica Iranica Published:2016


Abstract

Bronchiolitis obliterans (BO) is the most remarkable pulmonary sequels of war-related sulfur mustard inhalation. There is little if any data about long-term efficacy of associated BO treatment. Five years spirometric records of three groups of patients with obstructive pulmonary diseases (asthma, COPD, BO) and documented sulfur mustard inhalation were evaluated. The BO patients were treated with inhaled Seretide 125-250/25 (2 puffs BID), azithromycin (250 mg, three times/week) and N-acetylcysteine (1200-1800/day). Asthma and COPD patients were treated according to existing guidelines. Seventy-three (38 asthma, 16 COPD and 19 BO) patients completed the 5 years follow-up. Basal and final FEV1 in BO patients (2.69±0.81 and 2.39±0.65 respectively) were not significantly different from COPD patients (2.46±0.56 and 1.96±0.76 respectively). There was also no significant difference between the yearly FEV1 decline in BO patients compared to COPD patients (60±84 cc vs. 99±79 cc respectively, P=0.163). The non-significant difference of FEV1 decline in BO compared to COPD patients suggests the effectiveness of azithromycin, inhaled steroid and N-acetyl cysteine in BO patients. Considering safety and possible effectiveness, this treatment is recommended until more data is available from controlled clinical studies. © 2016 Tehran University of Medical Sciences. All rights reserved.